Kennedy Capital Management, Inc. Fibrogen Inc Transaction History

Kennedy Capital Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$37.97 - $60.16 $3.42 Million - $5.42 Million	-90,028 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $139,567 - $166,712	2,479 Added 2.83%	90,028 $5.47 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $1.29 Million - $1.86 Million	28,690 Added 48.74%	87,549 $5.48 Million
Q1 2018 May 14, 2018	SELL	$45.35 - $61.65 $43,399 - $58,999	-957 Reduced 1.6%	58,859 $2.72 Million
Q4 2017 Feb 13, 2018	BUY	$41.95 - $60.1 $2.51 Million - $3.59 Million	59,816	59,816 $2.84 Million

39.9M

343K

100K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $51.6M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.